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Abstract
Background: Lentiviral vectors are efficient vehicles for stable gene transfer in dividing and non-
dividing cells. Several improvements in vector design to increase biosafety and transgene
expression, have led to the approval of these vectors for use in clinical studies. Methods are
required to analyze the quality of lentiviral vector production, the efficiency of gene transfer and
the extent of therapeutic gene expression.
Results:  We compared lentiviral vector titration methods that measure pg p24/ml, RNA
equivalents/ml, transducing units (TU/ml) or mRNA equivalents. The amount of genomic RNA in
vector particles proves to be reliable to assess the production quality of vectors encoding non-
fluorescent proteins. However, the RNA and p24 titers of concentrated vectors are rather poor
in predicting transduction efficiency, due to the high variability of vector production based on
transient transfection. Moreover, we demonstrate that transgenic mRNA levels correlate well with
TU and can be used for functional titration of non-fluorescent transgenes.
Conclusion:  The different titration methods have specific advantages and disadvantages.
Depending on the experimental set-up one titration method should be preferred over the others.
Background
In our laboratory we routinely produce and apply vectors
derived from the human immunodeficiency virus type 1
(HIV-1). Since lentiviral vectors (LV) integrate stably into
the host-cell genome of non-dividing cells such as neu-
rons and in haematopoietic stem cells [1-3], they offer
great potential for gene therapeutic applications [4]. For
biosafety reasons, the HIV-1 genome has been modified
and cis and trans-acting viral sequences have been segre-
gated over 3 to 4 different plasmids [5,6]. Indeed, viral
structural and functional proteins can be provided in trans
and are encoded by 1 or 2 packaging plasmids while the
envelope plasmid encodes the glycoprotein of the vesicu-
lar stomatitis virus envelope (VSV-G) and a transfer plas-
mid encodes the transgene of interest flanked by all cis-
acting viral sequences necessary for packaging of the RNA
genome (reviewed by [7]). Production of lentiviral vectors
is routinely achieved by transient transfection of human
embryonic kidney (293T) cells using high concentrations
of the different plasmids, implicating the presence of
residual plasmid DNA in the vector preparation, even
after concentration. Transduction by lentiviral vectors
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matches a single-round infection and results in long-term
integration into the genome of both dividing and non-
dividing cells, forever linking the fate of the provirus with
that of the target cell. VSV-G pseudotyping of the lentiviral
vector particles not only broadens the tissue tropism of
the vector, but also stabilizes the particles allowing con-
centration to high titers by ultracentrifugation [8]. Since
the initial development of the lentiviral vector system
[2,5,6] the transfer plasmid was gradually optimized in
order to improve biosafety as well as to increase transduc-
tion efficiency. The self-inactivating (SIN) deletion in the
3' LTR [9] limits vector rescue and reduces the likelihood
of promoter activation after integration. The woodchuck
hepatitis virus posttranscriptional regulatory element
(WPRE) [10] stabilizes the transgene mRNA and the inser-
tion of the central polypurine tract/central termination
site (cPPT/CTS) sequence stimulates nuclear import [11].
Approval of lentiviral vectors for cell-marking and thera-
peutic studies in humans requires in-depth characteriza-
tion of vector titers and expression profiles of therapeutic
genes. Ample methods to evaluate lentiviral vector titers
have been described (reviewed by [12]). These methods
can roughly be divided into functional and non-func-
tional titration methods. The latter include p24 antigen
ELISA, assessment of the reverse transcriptase activity and
determination of the genomic RNA concentration in vec-
tor preparations by semi-quantitative northern blotting,
dot blot analysis or RT-qPCR. Generally these techniques
overestimate the functional vector titer and suffer from
following disadvantages: the p24 protein pool that is
quantified includes a variable amount of free p24 and p24
that originates from non-functional vector particles. Sim-
ilarly, RNA titers will also assess defective particles,
whereas the RT-assay merely demonstrates RT activity. A
more accurate, functional titer is determined by transduc-
tion of cells following limiting dilution of vector and sub-
sequent evaluation of reporter protein activity, (e.g. beta-
galactosidase positive cells) or by assessment of the
number of colony forming units following antibiotic
selection. The most widespread and straightforward tech-
nique to quantify functional vector titers employs eGFP
fluorescence and fluorescence-activated cell sorting
(FACS). However, FACS analysis of transgene expression
is restricted to fluorescent reporter proteins and cannot
discriminate cells with single or multiple integrations. In
strict sense, the definition of a functional vector titer is the
number of vector particles required to infect a cell, present
in a volume. In this regard, the best measurement of the
number of functional particles can be accomplished by
determination of the number of integrated proviral DNA
copies per cell by qPCR [13-15]. However, due to inser-
tion in regions with different chromatin packing, the inte-
grated proviral DNA results in varying transgene
expression levels. To overcome this drawback, Lizeé et al.
[15] described a RT-qPCR method to quantify lentiviral
mRNA copies following stable transduction in cell cul-
ture. Ultimately, the method of choice will depend on the
experimental set-up. Basic research and possible clinical
applications are in need of a universal, functional titration
method for any transgene-of-interest, for example by
qPCR. When analysing different internal promoters driv-
ing transgene expression quantification of the number of
integrated proviral DNA copies following titration on a
reference cell line is recommended. On the other hand, to
compare different lentiviral vector backbones comprising
additional cis-acting elements, a non-functional titration
method is preferred to normalize the number of vector
particles before assessing transduction efficiency.
In this study, we developed a quantitative RT-PCR assay,
for quantification of both genomic lentiviral RNA after
production and of transgene transcripts following trans-
duction. We opted for a one-step RT-qPCR to reduce both
sample handling time and variability. In addition, in con-
trast with the published methods, samples were amplified
alongside a RNA standard to correct for low reverse tran-
scriptase efficiency. The reliability of the different titration
methods (RT-qPCR, ELISA and FACS) was evaluated and
the methods were subsequently applied to assess vector
production quantitatively and qualitatively. Next, we ana-
lysed the correlation between transgene expression as
measured by FACS analysis and RT-qPCR. Although sev-
eral groups have reported on the use of TU/ml or pg p24/
ml to normalize vector transduction experiments [16,17],
a careful side-by-side analysis was hitherto absent. Here,
we normalized vectors for RNA and p24 values prior to
transduction and evaluated the transgene expression to
determine the best titration method to normalize lentivi-
ral vectors.
Results and discussion
Validation of a one-step RT-qPCR to determine lentiviral 
RNA content in concentrated vector preparations
A one-step real-time RT-qPCR for quantification of lenti-
viral vector RNA in concentrated vector preparations was
established. One-step RT-qPCR combines the reverse tran-
scriptase reaction and the amplification in a single tube,
reducing sample handling time and variability. Due to the
exponential nature of PCR amplification, a highly specific
and quantitative measurement in the linear range of
amplification can be performed with a TaqMan Probe,
labeled with a reporter fluorophore and a quencher at the
5' and 3' end, respectively. Primers and probe are directed
against the U5 region of the 5' LTR and the 5' end of the
gag gene, sequences that are present in all HXB2-derived
lentiviral vector constructs [18] (Figure 1A). A linear rela-
tion between the copy number and the fluorescent signal
intensity was observed over 6 logs (5.45 × 103 to 5.45 ×
108 RNA equivalents/reaction with a slope = -3.2) (dataBMC Biotechnology 2006, 6:34 http://www.biomedcentral.com/1472-6750/6/34
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not shown). Although quantification of lentiviral vectors
by real-time PCR has been described before [14], we are
the first to use an RNA standard. The use of an RNA stand-
ard takes into account the limiting amount of RNA that is
actually reverse-transcribed into cDNA. Indeed, a DNA
standard, as used in a two-step RT-qPCR, possibly under-
estimates the RNA copy number. Because lentiviral vec-
tors are produced by triple transient transfection of 293T
cells, plasmid DNA is present in the concentrated vector
requiring a DNase treatment of each lentiviral vector sam-
ple prior to RT-qPCR (results not shown). Alternatively,
plasmid DNA contamination could be overcome by the
design of stable producer cell lines [19-21]. Next, the
reproducibility of RNA extraction and RT-qPCR were vali-
dated by comparing the RT-qPCR results of a CH-eGFP-
WS lentiviral vector subjected to three independent RNA
extractions (Table 1). Subsequently, each sample was run
in triplicate in the RT-qPCR. The coefficient of variation
(CV) was 6 ± 4 % between triplicate samples of the same
RNA extraction and 38 ± 22 % for three independent RNA
extractions (data not shown).
Next, three different lentiviral vectors (H-eGFP, H-eGFP-
WS and CH-eGFP-WS) were produced in parallel (Figure
1B). H-eGFP-WS contains the WPRE, known to affect
mRNA stability [10] while the cPPT/CTS sequence in CH-
eGFP-WS improves the transduction efficiency [22,23].
For each vector the RNA equivalents, transducing units
(TU/ml) and p24 concentrations were determined to
compare the different titration methods. Obviously, a
clear difference between the lentiviral vectors was only
evidenced by measuring the transducing titer (TU/ml),
whereas the RNA and p24 concentration were similar for
all vector backbones, pointing out that the packaging effi-
ciency was comparable for the different constructs. In
addition, although each functional vector particle (1
transducing unit) carries two RNA copies implying a the-
oretical ratio of 0.5, in reality the TU/RNA ratio ranged
between 0.0009 and 0.0832 (Table 1). The TU/pg value
ranged between 11 and 351. Both TU/pg and TU/RNA
estimate the specific activity and correlate well with
improved lentiviral vector backbone design. Table 1
shows a 6 and 8-fold increase in specific activity, when
comparing the H-eGFP with H-eGFP-WS vector and a 31
and 68-fold increase when comparing the H-eGFP with
the CH-eGFP-WS vector for TU/pg and TU/RNA respec-
tively. Although the specific activities correlate well with
the vector backbone, the differences between TU/pg and
TU/RNA demonstrate that this is not an absolute value.
Indeed, variations in TU, p24 and RNA titer may also be
attributed to the inherent variability of transient transfec-
tion used for vector production, which is also dependent
on the number of cells plated or the state of the producer
cells. The TU/pg and TU/RNA values thus give an indica-
tion of the quality of the vector production but are sub-
jected to the variable amounts of p24 and RNA produced
by the cells.
It has been shown before that RNA values overestimate
functional eGFP titers (TU/ml) by 200- to 10,000-fold
[13-15,24]. In our hands, using a RNA standard, we
detected an approximately 10- to 1000-fold difference
between the eGFP and RNA titers depending on the vector
backbone. The discrepancy between the RNA and TU titer
between several groups may be dependent on the vector
backbone or other factors. First, the possibility exists that
incomplete, defective genomes are integrated in the vector
particles [25]. Second, during transduction, part of the
functional vector particles may stay in the cell culture
medium and it has been shown that changes in inoculum
volume and transduction time all influence transducing
titers [17]. Third, for lentiviral vectors it was shown previ-
ously by two independent groups that only ~10% to
~18% of the initial reverse transcribed genomes actually
Overview of primer sets and lentiviral vector constructs Figure 1
Overview of primer sets and lentiviral vector con-
structs. (A) Schematic representation of CH-eGFP-WS len-
tiviral vector with the corresponding amplicons of the 
different primer sets (LTR-gag, GFP and WPRE). Primer 
sequences are represented in small caps and probe 
sequences are in bold. (B) Schematic representation of differ-
ent lentiviral vector constructs. The construct was optimized 
to increase transduction efficiency (cPPT and WPRE) and 
biosafety (SIN) as described before [9, 10, 23].BMC Biotechnology 2006, 6:34 http://www.biomedcentral.com/1472-6750/6/34
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integrate in the host-cell DNA of 293T cells after transduc-
tion, probably due to degradation in the cytoplasm
[18,26]. Fourth, not all integrated proviral genomes may
result in detectable transgene expression. Several groups,
except for one [14], demonstrated that the proviral-based
qPCR overestimates eGFP titers varying from 6-to 60-fold
[13,15,27], probably due to integration in DNA regions
with reduced transcriptional activity.
Quantification of genomic lentiviral vector RNA using 
different primer sets
The amplicon of the primer set that is used to quantify the
lentiviral vector RNA is located in the 5'LTR of the RNA
genome. Hence, lentiviral vector RNA containing a pack-
aging signal but truncated at the 3' end can still be incor-
porated into vector particles, thereby affecting both RNA
titers and p24 values, but eventually resulting in non-
functional vectors. Therefore, the LTR-gag primer/probe
set was compared to a primer/probe set directed against
the eGFP transgene and a WPRE primer/probe set (Figure
2A) on the same plasmid DNA standard to reduce varia-
tion between different standards. As shown in Table 2, all
primer sets were equally efficient in amplifying the pCH-
eGFP-WS plasmid DNA. Next, we quantified lentiviral
vector RNA titers (in triplicate) by one-step RT-qPCR for
two independent CH-eGFP-WS vector preparations com-
paring the three primer sets. Cycle threshold values (Ct,
i.e. the cycle number at which a significant increase in flu-
orescence above base-line signal is detected) did not differ
significantly between the WPRE, LTR-gag or eGFP primer
sets. To control for contaminating mRNA transcripts from
producer cells that may be concentrated together with the
vector particles, we performed a transient transfection
without packaging plasmid. Since expression from our
transfer plasmid is Tat-dependent, omission of the pack-
aging plasmid, resulted in a 1000-fold (≥ 9 Ct) reduction
in vector titers as quantified with the LTR primers. Con-
tamination with eGFP- mRNA, transcribed from the inter-
nal CMV promoter, was verified in the same experiment
but using eGFP primers. A 100-fold (≥ 6 Ct) reduction in
eGFP-mRNA was detected indicating that eGFP-mRNA
contaminates the vector preparations to a slightly higher
extent. Still, the great majority of the amplified cDNA is
derived from full-length RNA constructs that are incorpo-
rated in the viral particles. Therefore, the discrepancy
between RNA and functional titer (Table 1) is not due to
the presence of incomplete genomic RNA.
Comparison of lentiviral vector titration methods
Most frequently used titration methods for lentiviral vec-
tors measure the p24 antigen concentration (pg p24/ml)
by ELISA or the number of transducing units (TU/ml) by
FACS analysis after limiting dilution in cell culture.
Whereas the p24 concentration measures both functional
and non-functional vector particles, the TU strictly meas-
Comparison of lentiviral vector titration methods Figure 2
Comparison of lentiviral vector titration methods. 
CH-eGFP-WS vector was serially diluted (1/2) and subjected 
to RT-qPCR, ELISA and FACS analysis after transduction of 
293T cells, to determine the linearity of the different titration 
methods. The correlation coefficients are representative for 
3 independent experiments. The asterix (*) represents values 
that were not included in the linear regression.
Table 1: Evaluation of the different titration methods
RNA c/ml TU/ml pg p24/ml TU/pg TU/RNA
Cell factories
CH-eGFP-WS 2.68 ± 0.38 × 1010 2.23 ± 1.10 × 109 9.8 ± 5.3 × 106 228 0.0832
Culture dishes
H-eGFP 5.63 ± 0.50 × 1010 5.05 ± 4.9 × 107 4.67 ± 4.5 × 106 11 0.0009
H-eGFP-WS 3.83 ± 2.25 × 1010 2.92 ± 2.5 × 108 4.83 ± 4.70 × 106 60 0.0076
CH-eGFP-WS 2.73 ± 1.59 × 1010 1.68 ± 1.3 × 109 4.79 ± 3.45 × 106 351 0.0615
The lentiviral vector CH-eGFP-WS was produced in cell factories and concentrated by centrifugation as described before [8]. Three independent 
RNA extractions were carried out on this vector and RNA equivalents were determined by RT-qPCR. Mean values ± standard deviation are 
shown. Next, three lentiviral vectors with different transfer plasmids, H-eGFP, H-eGFP-WS and CH-eGFP-WS, were produced in parallel in cell 
culture dishes. RNA equivalents (RNA/ml), transducing units (TU/ml) and p24 concentrations (pg p24/ml) were determined by RT-qPCR, titration 
and ELISA, respectively. The TU/pg and TU/RNA value indicate the specific activity of the vector constructs and correlate well with the vector 
backbones. The data represent the mean values ± standard deviation of three independent productions per lentiviral vector.BMC Biotechnology 2006, 6:34 http://www.biomedcentral.com/1472-6750/6/34
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ures functional vector particles that result in the expres-
sion of a fluorescent reporter protein. To compare the
linearity, reproducibility and variability of the different
methods, a CH-eGFP-WS lentiviral vector was serially
diluted (12 steps of 1/2 dilution) and subjected to RNA
extraction, p24 ELISA and transduction in cell culture. All
titration methods correlated well with the initial dilution
series: r2 = 0.99 for RNA/ml after RT-qPCR, r2 = 0.93 for
TU/ml after FACS and r2 = 0.94 for p24/ml after ELISA
(Figure 2). When determining transduction titers after
limiting dilution, one uses only dilutions at MOI<<1
resulting in low percentage of transduced cells, to mini-
mize the risk for multiple integrations. Titration depends
on the total volume that is covering the cells, the time of
incubation with the particular vector dilution and the cell
type used. Prolonged incubation or delivery at the same
MOI in only half of the volume will affect titers signifi-
cantly. Nevertheless, using standardized conditions, these
methods allow a good estimation of vector quality and tit-
ers. As a control, we checked the correlation between vec-
tor dilution and transduction efficiency (TE, i.e. the
percentage of transduced cells) as measured by FACS. The
most concentrated vector dilutions resulted in near 100%
transduction, whereas the most diluted samples resulted
in TEs near zero (* in Figure 2) and were omitted from the
linear regression. Hence, the TE correlated only over 9
dilutions with r2 = 0.95.
Moreover, to estimate the variability within each test, we
calculated the coefficients of variation (CV) for the differ-
ent methods. The CV for the RNA/ml, the TU/ml and the
pg p24/ml were respectively 39%, 78% and 103% on
average. In conclusion, the RNA and p24 concentration as
well as the functional titer are reliable parameters to assess
the order of magnitude of vector titers. However, absolute
numbers differ between samples as shown by the CV. The
highest CV was obtained for the p24 ELISA. Other disad-
vantages of the p24 measurement are the restricted linear
range (13–200 pg/ml) and the accompanying extensive
dilution of the concentrated vector sample that is required
and affects reproducibility. The high CV for the TU/ml
may be due to variations in the cell number upon trans-
duction or random integration in the genome, resulting in
differences in transgene expression level.
Analysis of gene expression after normalization for p24 or 
vector RNA concentration
To evaluate vector optimization (promoter choice, inser-
tion of enhancer elements) it is important to normalize
vector preparations prior to transduction. Functional titra-
tion methods such as FACS analysis after limiting dilution
cannot be used in this case, since this titer is dependent on
the specific backbone. Here we compared the use of p24
and vector RNA concentration for normalization of CH-
eGFP-WS vectors prior to transduction. Separate produc-
tions of CH-eGFP-WS-derived lentiviral vector were pre-
pared and RNA equivalents and p24 concentration
determined within a single test run to minimize inter-
assay variation. The percentage of eGFP-positive cells was
determined by FACS 3 days later (Table 3). A high varia-
tion was observed between the different productions
amounting to a CV of around 50% for both techniques.
The variability is probably a combination of variation due
to the triple transient transfection procedure, which
results in variable protein expression and viral genome
production for separate productions, and variation of the
technique itself (see before). High variations in p24 values
were already described by Logan and colleagues [16] who
measured p24 values ranging from 67.4 ng/ml to 583.7
ng/ml even for vectors produced in parallel. Moreover, the
relative transduction values for the productions differ for
both RNA and p24 measurements, indicating a poor cor-
Table 2: Measurement of viral RNA in concentrated lentiviral vector preparations
Ct value
DNA Standard LTR primers eGFP primers WPRE primers
5.0 × 108 15.51 ± 0.01 15.65 ± 0.04 15.45 ± 0.06
5.0 × 107 17.57 ± 0.01 17.79 ± 0.10 17.51 ± 0.01
5.0 × 106 18.97 ± 0.06 19.11 ± 0.08 20.11 ± 0.05
5.0 × 105 22.06 ± 0.17 21.82 ± 0.07 22.59 ± 0.03
5.0 × 104 25.91 ± 0.05 24.06 ± 0.06 26.13 ± 0.04
RNA extracts
CH-eGFP-WS 22.87 ± 0.05 22.5 ± 0.02 22.04 ± 0.03
CH-eGFP-WS 16.15 ± 0.02 16.57 ± 0.03 16.43 ± 0.05
Primer/probe sets annealing to the front (LTR), the centre (GFP) or at the end (WPRE) of the genomic RNA of lentiviral vectors were used to 
determine to what extent full-length genomic vector RNA is incorporated into lentiviral vector particles. In one-step RT-qPCR assays with the 
different primer/probe sets comparable threshold cycles (Ct) were detected when amplifying a dilution series of the pCH-eGFP-WS transfer 
plasmid (DNA standard) or RNA extracts of two representative CH-eGFP-WS vector preparations. Mean Ct values ± standard deviation for 3 
amplifications of the same sample are shown.BMC Biotechnology 2006, 6:34 http://www.biomedcentral.com/1472-6750/6/34
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relation between both parameters and reflecting the fact
these are dependent on transfection of transfer and pack-
aging plasmid, respectively. Both p24 and RNA concentra-
tions can be used for comparison of vector performance if
minimizing intrinsic variability of the test by single run
analysis and vector productions in parallel. In conclusion,
both the RNA titer and p24 values are poor in predicting
gene transfer efficiency. Still, they can be used for normal-
ization of vector preparations.
Evaluation of the reliability of the titration methods to 
assess lentiviral vector production quality and kinetics
In our vector core lentiviral vectors are produced on a
weekly basis. Cell supernatant containing lentiviral vec-
tors is routinely harvested in serum-free medium at 2 and
3 days after triple transient transfection [8]. To analyze the
kinetics of lentiviral vector productions in further detail
and to investigate the possibility of harvesting for a longer
time period, a CH-eGFP-WS-derived vector was produced
in two 2-layer cell-factories, as described earlier [8]. The
supernatant was harvested once daily for five consecutive
days (day 2 till day 6 post-transfection) and subsequently
concentrated by low-speed centrifugation (5 hrs, 26,000
g). Figure 3 displays the kinetics of the different parame-
ters during days of production. From day 3 onwards, vec-
tor titers start to decline, as evidenced by the three
titration methods. Notwithstanding the drop in vector tit-
ers, there is still a significant amount of high-quality vec-
tor produced at day 4 and 5. The specific activity in TU/
RNA increases at each harvesting day, whereas the specific
activity in TU/pg displays comparable values each day
(Figure 3). These results indicate that at later time points,
vector with the highest specific activity (TU/RNA) is pro-
duced. One can envision that transient transfection will
not be optimal at later days of production and expression
will be gradually lost upon further division of the pro-
ducer cells, resulting in a 10- to 100-fold decline in vector
concentrations (TU/ml, RNA/ml and pg p24/ml). In addi-
tion, small loss of producer cells upon medium replace-
ment will further result in decreased titers in time. Based
on these results and for practical reasons, we decided to
harvest our state-of-the-art vectors at day 2 and at day 3
Kinetics of lentiviral vector production Figure 3
Kinetics of lentiviral vector production. The CH-eGFP-
WS-derived lentiviral vector was produced in two CF2 mod-
ules by triple transient transfection in serum-free medium. 
Starting at 2 days post-transfection, cell-culture medium was 
harvested once a day for five consecutive days and concen-
trated by low-speed centrifugation. The p24 content (pg p24/
ml) of vector preparations was determined by ELISA, the 
transducing titers (TU/ml) by FACS analysis and the RNA 
equivalents (RNA/ml) by one-step RT-qPCR with LTR prim-
ers. Data represent the mean value ± standard deviation and 
represent 3 independent experiments. A decrease in vector 
titer starting at 3 days post-transfection was evidenced by all 
methods. The specific activities (TU/pg and TU/RNA) are 
depicted in the inset.
Table 3: Evaluation of the transduction efficiency after normalization for RNA or p24
Equal p24 Equal RNA
Vector production 
number
TE % relative TE TE% relative TE
11A 39.17 1.00 18.02 1.00
11B 4.67 0.12 4.2 0.23
116 29.6 0.76 21.86 1.21
126 11.19 0.29 10.64 0.59
78 31.18 0.80 9.15 0.51
median ± SD 30 ± 15 11 ± 7
CH-eGFP-WS-derived lentiviral vectors were produced in separate productions indicated by a production number. RNA and p24 concentrations 
were determined in the same assays to reduce inter-assay variation. Before transduction of 293T cells, vectors were normalized for RNA or p24 
concentration. Two days later, cells were harvested to determine the percentage of transduced cells by FACS (TE or transduction efficiency). TE 
values relative to the first production are presented as well. A high variation was observed after normalization for either RNA or p24.BMC Biotechnology 2006, 6:34 http://www.biomedcentral.com/1472-6750/6/34
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post-transfection since for most experiments high-titer
vector is needed.
Besides quantifying lentiviral vector concentration, the
optimized RT-qPCR also provides us with an alternative
method to evaluate vector quality after production.
Indeed, most transfer plasmids encode non-fluorescent
transgenes, leaving the p24 concentration as the only
quality control. To assess the reliability of the different
titration methods to analyse vector production quality, a
CH-eGFP-WS vector was produced in 2-layer cell factories
by triple transient transfection of the envelope, the pack-
aging and the transfer plasmid. In parallel with the stand-
ard production, three additional productions were
performed replacing either one of the three plasmids with
a control plasmid in order to maintain a constant transfec-
tion efficiency. Titers were determined (pg p24/ml, RNA/
ml and TU/ml) following vector concentration by low-
speed centrifugation (Table 4). Whereas the standard vec-
tor production generated fully functional vector particles
as demonstrated by the functional titer (TU/ml), omis-
sion of any of the other plasmids during production
resulted in no detectable functional titers. As expected,
omitting the transfer plasmid (encoding the viral vector
genome) during production resulted in the production of
empty, non-functional vector particles, as reflected by the
absence of both a functional titer (TU/ml) and an RNA
titer. Surprisingly, the p24 concentration was not signifi-
cantly different from the standard vector. Indeed, the
mere presence of the packaging plasmid resulted in nor-
mal p24 values in all production protocols. Exclusion of
the envelope plasmid encoding VSV-G during the vector
production resulted in p24 and RNA titers comparable to
those of a normal vector production, whereas the func-
tional titer remained below detection limit (TU/ml),
inferring the generation of vector particles defective in cel-
lular uptake. Furthermore, this result indicates that trans-
duction by our lentiviral vector is not skewed by pseudo-
transduction with free eGFP, DNA or RNA. Obviously,
omission of the packaging plasmid resulted in the absence
of p24 antigen and the generation of non-functional par-
ticles (no TU/ml). Although the RNA titer obtained was
reduced by three logs, RNA transcripts apparently contam-
inate the vector preparation to a limited extent. This is in
accordance with results from Ikeda et al [24], who also
demonstrated that without Gag-Pol the RNA secretion
represented only 0.1 % of the packaged RNA. In addition,
this result confirms the conclusions drawn from table 2,
i.e. mainly full-length RNA transcripts are incorporated in
lentiviral vector constructs.
Our results clearly demonstrate that the p24 concentra-
tion is the least reliable for the evaluation of functional
vector particles after vector production. Nevertheless, it is
a fast method that can be used as quality control for rou-
tine vector production. Logan and colleagues [16]
described how manipulation of the amounts of transfer,
packaging or envelope plasmids did not alter the specific
activity (TU/pg p24) but rather influenced the vector con-
centration in the supernatant (TU/ml and pg p24/ml).
However, if non-fluorescent transgenes are encoded, a
functional titer cannot be determined, and one has to rely
on the RNA concentration indicating the presence of
genomic RNA. How this RNA titer relates to the functional
titer is dependent on the vector construct (see Table 1),
the transgene and the promoter, and requires further anal-
ysis of the integrated proviral genome by qPCR or of the
transgene expression level by RT-qPCR, Western blotting
or immunocytochemistry after transduction.
Evaluation of transgene expression by RT-qPCR
Eventually, future clinical applications of gene transfer
vectors will necessitate accurate determination of expres-
sion levels of any therapeutic transgene. Lizee and col-
legues [15] successfully applied a quantitative and generic
two-step RT-qPCR method (with a DNA standard) to
determine mRNA expression levels in transduced cells
with a primer-probe set located in the WPRE, present in
the 3' UTR of the transgenic mRNA. In contrast, we opti-
mized a one-step RT-qPCR also with a WPRE primer-
probe set but with a RNA standard to quantify expression
levels (Figure 1A). To assess reproducibility, a CH-eGFP-
Table 4: Reliability of the titration methods to assess lentiviral vector production quality
packaging plasmid envelope plasmid transfer plasmid RNA/ml TU/ml pg p24/ml
+ + + 6.18 ± 1.71 × 109 1.07 ± 0.53 × 107 4.10 ± 2.05 × 105
+ + - below detection limit below detection limit 2.10 ± 0.64 × 105
+ - + 2.36 ± 0.63 × 1010 below detection limit 1.27 ± 0.32 × 105
- + + 8.04 ± 1.64 × 106 below detection limit below detection limit
Lentiviral vectors were produced in parallel in cell culture dishes by triple transient transfection with transfer, envelope and packaging plasmids. 
Omission of a plasmid is indicated. RNA equivalents (RNA/ml), transducing units (TU/ml) and p24 concentration (pg p24/ml) were determined after 
concentration of LV by low-speed centrifugation. For the CH-eGFP-WS vector, the titer was measured with all three methods. In the absence of 
the packaging plasmid, encoding for structural proteins, the RNA titer decreased 1000-fold while p24 and TU titers were below detection limit. 
Omission of the envelope plasmid during the vector production resulted in p24 and RNA titers comparable with those of a normal production 
albeit with a non-detectable functional titer. Vector production without transfer plasmid only yielded a positive p24 titer. Mean values ± standard 
deviation for 3 measurements of the same sample are shown.BMC Biotechnology 2006, 6:34 http://www.biomedcentral.com/1472-6750/6/34
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WS lentiviral vector was serially diluted (1/10) on 293T
cells. Transgene expression (eGFP) was measured both by
FACS and by RT-qPCR. A primer-probe set designed for
human RNase P, a housekeeping gene, was added to each
sample to allow normalization to the total RNA content.
Again, an RNA standard (5 × 103 to 5 × 108 RNA equiva-
lents/reaction with a slope = -3.2) was taken along with
samples and no amplification controls. Subsequently, rel-
ative values were calculated and presented as the number
of RNA copies per ng total RNA (mRNAc/ng). The over-all
transduction efficiency was calculated by multiplying the
percentage of eGFP-positive cells (TE) and the mean fluo-
rescence intensity (MFI). As demonstrated in Figure 4, len-
tiviral vector transgene expression (as measured by FACS)
and transgene RNA expression (as measured by RT-qPCR)
strongly correlate (correlation coefficient r2 = 0.97), indi-
cating that this method can be used to measure non-fluo-
rescent transgene expression. Differences in MFI are
observed and are related to the amount of eGFP expressed
in the cells, which may vary depending on the integration
site or the integrated copy number and depend on the
internal promoter and the cell type. Differences in mRNA
expression levels are also depending on these factors, as
shown by the correlation between TE and mRNAc/ng (r2
= 0.7). Hence, this method is an alternative for FACS anal-
ysis of fluorescent genes but does not discriminate
between multiple integrations. Several DNA-based quan-
titative PCRs for integrated proviral genomes are
described but are known to overestimate eGFP titers by 6-
to 60-fold [13,15,27], since not all integrated vectors con-
tribute to active gene expression. Therefore, the RNA
transgene expression level correlates best with the actual
protein expression level and can replace FACS analysis for
non-fluorescent transgenes, although this method is more
laborious and more expensive. Moreover, a more than 50-
fold difference in vector titer (TU/ml) was reported by
changing the conditions of the transduction process, such
as inoculum volume, the type and number of target cells
and the length of vector exposure to target cells [17].
Therefore standardization of the exact procedure of titra-
tion remains of uttermost importance.
Conclusion
In this paper, commonly used methods for titration of
lentiviral vectors were evaluated and may serve as a guide
for newcomers in the field. For basic studies and eventu-
ally clinical trials, it is imperative that the performance
characteristics and the variability inherent with these titra-
tion methods are known.
Due to the transient nature of a lentiviral vector produc-
tion, variations in p24, TU and RNA levels inherent to the
production procedure were demonstrated by ELISA, FACS
analysis and RT-qPCR, respectively. These methods can be
used to measure vector titers, although absolute numbers
may vary even within the same run. Nor RNA nor p24 tit-
ers, can predict a functional titer, since the functional titer
is dependent on the vector construct and the cell type used
for transduction. The TU/RNA and TU/pg ratios reflect the
specific activity of a lentiviral vector construct and were
demonstrated to correlate well with the vector backbone.
Normalization of vector productions based on RNA or
p24 values are hampered by variability due to the tran-
sient transfection and the titration method and should be
taken into consideration. Moreover, to assess the quality
of lentiviral vector productions encoding non-fluorescent
genes, the RNA titer is the most reliable, since p24 titers
were not affected by omission of the transfer plasmid. We
also demonstrated that the quantitative analysis of trans-
gene mRNA levels correlates very well with the eGFP fluo-
rescence as measured by FACS and hence can be used as
an alternative for titration of vectors encoding non-fluo-
rescent transgenes or determination of the transgene
expression levels in transduced cells.
Correlation of eGFP fluorescence and mRNA transgene  expression levels Figure 4
Correlation of eGFP fluorescence and mRNA trans-
gene expression levels. Four independently produced 
preparations of CH-eGFP-WS-derived lentiviral vector were 
serially diluted (1/10) prior to transduction of 293T cells. 6 
days later, cells were harvested for eGFP analysis by FACS or 
RNA extraction and subsequent RT-qPCR with primers and 
probe directed against WPRE to measure transgene expres-
sion and against RNAse P to normalize for total RNA con-
tent. Total eGFP expression was measured by multiplying the 
percentage of transduced cells (TE) with the mean fluores-
cence intensity (MFI). The transgene mRNA level is given as 
the number of mRNA copies normalized to the total RNA 
content (RNAc/ng). These values correlate strongly with 
each other (r2 = 0.97).BMC Biotechnology 2006, 6:34 http://www.biomedcentral.com/1472-6750/6/34
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Methods
Cell lines and lentiviral vector transduction
293T cells were maintained in Dulbecco's modified
Eagle's medium (DMEM; Gibco BRL, Merelbeke, Bel-
gium) supplemented with 10% heat-inactivated foetal
calf serum (FCS, Harlan Sera-Lab Ltd., International Med-
ical, Brussels, Belgium) and 100 U/mL Penicillin and 100
μg/mL Streptomycin (Gibco BRL). Chinese hamster ovary
cells, CHO-K1 were maintained in Ham's F12K medium
(NutMix F12, Gibco BRL) supplemented with 5% heat-
inactivated FCS and 20 μg/ml gentamicin (Gibco BRL).
Both cell lines were cultivated at 37°C in a humidified
atmosphere containing 5% CO2. Transductions of CHO-
K1 or 293T cells with HIV-1 based lentiviral vectors were
carried out in 96-well plates with 10-fold serial dilutions
of lentiviral vector preparations. Vector was added to the
cells in their corresponding medium supplemented with
1% FCS. After 4 hours of incubation, the medium was
refreshed. Three days later, cells were removed and fixed
in 2% paraformaldehyde prior to determination of titers
(TU/ml) by limiting dilution and FACS.
The coefficient of variation (relative standard deviation)
was determined for the different titration methods, which
is a measure for the biological and experimental variation
and is calculated as follows: stdev/mean × 100.
Lentiviral vector production
HIV-1-derived lentiviral vector particles, pseudotyped
with the VSV-G envelope, were produced by transfecting
293T cells with a second generation packaging plasmid
lacking vif, vpr, vpu and nef genes (pCMVΔR8.91), a plas-
mid encoding the envelope of VSV (pMDG) and a pHR'-
derived transfer plasmid coding for eGFP as a reporter
gene. Lentiviral vectors were produced as described earlier
[8]. Lentiviral vector stocks were normalized based on p24
antigen content (HIV-1 p24 ELISA kit; PerkinElmer,
Milano, Italy). Transduction titers for vectors encoding
eGFP were determined by FACS analysis after limiting
dilution on CHO-K1 cells.
One-step real-time RT-qPCR
RNA content of lentiviral vectors was quantified with a
one-step RT-qPCR that allows reverse transcription (RT)
and amplification to take place in the same reaction tube.
After RNA extractions of concentrated vector preps with
the RNAqueous®-Micro Kit (Ambion, Cambridgeshire,
United Kingdom) a DNase treatment (RNAqueous-Micro
Kit) was carried out to eliminate residual plasmid DNA
from the vector production according to the manufac-
ture's protocol. RNA was amplified using the TaqMan®
One-Step RT-PCR master mix reagents kit (Applied Bio-
systems, Lennik, Belgium) with primers and probe located
in the eGFP transgene, the LTR or the WPRE. Forward and
reverse primers were developed with the Primer Express
Software (Applied Biosystems) and are specific for eGFP:
5'- GGAGCGCACGATCTTCTTCA-3' and 5'-AGGGT-
GTCGCCCTCGAA-3'; for LTR 5'-TGTGTGCCCGTCTGTT-
GTGT-3' and 5'-GAGTCCTGCGTCGAGAGAGC-3' [18];
and for WPRE 5'-CCGTTGTCAGGCAACGTG-3' and 5'-
AGCTGACAGGTGGTGGCAAT-3' [15]. Following Taq-
Man probes were used : for eGFP, 5'-FAM-CTACAAGAC-
CCGCGCCGAGGTG-TAMRA-3'; for LTR, 5'-FAM-
CAGTGGCGCCCGAACAGGGA-TAMRA-3' [18] and for
WPRE, 5'-FAM-TGCTGACGCAACCCCCACTGGT-
TAMRA-3' [15]. Amplicon sizes are for eGFP: 75 base pairs
(bp), for LTR: 143 bp for WPRE: 85 bp. The kit contains
the Multiscribe™ Reverse Transcriptase (MuLV) which car-
ries out the RT-step (30 minutes at 48°C) and AmpliTaq
Gold enzyme for amplification (40 cycli at 95°C for 15
seconds, followed by 1 minute at 60°C). Reactions were
analyzed using the ABI Prism model 7700 sequence detec-
tion system (Applied Biosystems). During each run a 'no
amplification control' (NAC) was included for each sam-
ple (i.e. sample without RT-enzyme) to detect residual
DNA contaminants and this value was subtracted. To nor-
malize the mRNA values of expressed transgenes to the
total RNA content in the sample, additional primers and
a VIC-TAMRA-labeled probe directed against the RNAse P
housekeeping gene were included in the sample mixture
(RNAse P control reagents kit, Applied Biosystems) and
values were corrected for the total amount of RNA in the
sample. (FAM: 6-carboxyfluorescein; TAMRA: 6-carbox-
ytetramethylrhodamine)
Generation of RNA standards by in vitro transcription
For quantification of the extracted vector, an RNA stand-
ard was prepared by in vitro transcription. Therefore, an
LTR- (302 bp) or WPRE-fragment (640 bp) was cloned
into pSPT19 or pBluescript, respectively. The plasmid was
linearized by a restriction digest with an enzyme located
downstream of the cloned fragment, followed by in vitro
transcription according to the manufacturer's protocol
(RNA labelling kit, Roche, Brussels, Belgium). The result-
ing RNA was quantified using a spectrophotometer and
standard curves were generated by 1/10 serial dilutions.
During each one-step RT-qPCR, the RNA standard was run
together with the samples in duplicate and the NACs.
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